|
Wechseljahre:
Pflanzliche Medikamente die Extrakte aus der
Traubensilberkerze
enthalten wirken bei der
Therapie typischer Wechseljahrsbeschwerden nicht
besser als ein unwirksames Scheinmedikament.
An der Universität von
Washington wurde untersucht, ob aus dem Traubensilberkerzenrhizom
gewonnene Wirkstoffe in der Lage sind, die für
die Wechseljahre der Frau typischen
vasomotorischen Symptome (z.B. Hitzewallungen)
zu bessern. Die in den Annals of Internal
Medicine publizierte Untersuchung wurde unter
Beteiligung von 351 Frauen (52% Frauen in der
Menopause und 48% in der Postmenopause) als
Doppelblind-Studie konzipiert und durchgeführt.
Die Frauen klagten im Schnitt über 2 oder mehr
"Hitzewallungen" pro Tag. Im Verlauf der
Untersuchung konnten nach 3, 6 und 12 Monaten
keine statistisch signifikanten Unterschiede
zwischen den Therapiegruppen und den
Anwenderinnen der Scheinmedikamente (Placebo)
gefunden werden.
weitere Informationen zum
Thema:
Therapiestudie 2006
Mayo Clinic and Mayo Foundation
mehr
Cimicifugae
racemosae rhizoma -
Traubensilberkerzenwurzelstock
mehr
Ann Intern Med. 2006 Dec
19;145(12):869-79.
Treatment of vasomotor symptoms of menopause
with black cohosh, multibotanicals, soy, hormone
therapy, or placebo: a randomized trial.
Newton KM, Reed SD, LaCroix AZ, Grothaus LC,
Ehrlich K, Guiltinan J.
Group Health Center for Health Studies, the
University of Washington, and Fred Hutchinson
Cancer Research Center, Seattle, Washington
98101, USA. newton.k@ghc.org
BACKGROUND: Herbal supplements are widely
used for vasomotor symptoms.
OBJECTIVE: To test
the efficacy of 3 herbal regimens and hormone
therapy for relief of vasomotor symptoms
compared with placebo.
DESIGN: 1-year
randomized, double-blind, placebo-controlled
trial conducted from May 2001 to September 2004.
SETTING: Group
Health, Washington State.
PARTICIPANTS: 351
women age 45 to 55 years with 2 or more
vasomotor symptoms per day; 52% of the women
were in menopausal transition and 48% were
postmenopausal.
MEASUREMENTS: Rate and intensity
of vasomotor symptoms (1 = mild to 3 = severe),
and Wiklund Vasomotor Symptom Subscale.
INTERVENTIONS: 1)
Black cohosh, 160 mg daily; 2) multibotanical
with black cohosh, 200 mg daily, and 9 other
ingredients; 3) multibotanical plus dietary soy
counseling; 4) conjugated equine estrogen, 0.625
mg daily, with or without medroxyprogesterone
acetate, 2.5 mg daily; or 5) placebo.
RESULTS: Vasomotor symptoms per day, symptom intensity,
Wiklund Vasomotor Symptom Subscale score did not
differ between the herbal interventions and
placebo at 3, 6, or 12 months or for the average
over all the follow-up time points (P > 0.05 for
all comparisons) with 1 exception: At 12 months,
symptom intensity was significantly worse with
the multibotanical plus soy intervention than
with placebo (P = 0.016). The difference in
vasomotor symptoms per day between placebo and
any of the herbal treatments at any time point
was less than 1 symptom per day; for the average
over all the follow-up time points, the
difference was less than 0.55 symptom per day.
The difference for hormone therapy versus
placebo was -4.06 vasomotor symptoms per day for
the average over all the follow-up time points
(95% CI, -5.93 to -2.19 symptoms per day; P <
0.001).
LIMITATIONS: The
trial did not simulate the whole-person approach
used by naturopathic physicians. Differences
between treatment groups smaller than 1.5
Vasomotor symptoms per day cannot be ruled out.
CONCLUSION:
Black
cohosh used in isolation, or as part of a
multibotanical regimen, shows little potential
as an important therapy for relief of vasomotor
symptoms.
Clinical Trials Registration number:
NCT00169299.
|
